These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 31650508)

  • 1. Measure of adherence to direct-acting antivirals as a predictor of the effectiveness of hepatitis C treatment.
    Campos Fernández de Sevilla MÁ; Gallego Úbeda M; Tovar Pozo M; García-Cabrera E; Monje García B; Tutau Gómez F; Delgado Téllez de Cepeda L; Iglesias-Peinado I
    Int J Clin Pharm; 2019 Dec; 41(6):1545-1554. PubMed ID: 31650508
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Implementation of a pharmaceutical care program for patients with hepatitis C treated with new direct-action antivirals.
    Campos Fernández de Sevilla MÁ; Gallego Úbeda M; Heredia Benito M; García-Cabrera E; Monje García B; Tovar Pozo M; Delgado Téllez de Cepeda L; Iglesias-Peinado I
    Int J Clin Pharm; 2019 Apr; 41(2):488-495. PubMed ID: 31028599
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Feasibility and acceptability of adherence support for direct acting antiviral therapy for hepatitis C in a low-threshold primary health-care opioid agonist treatment program.
    Chronister KJ; Lothian R; Gilliver R; Kearley J; Read P
    Drug Alcohol Rev; 2019 Feb; 38(2):185-189. PubMed ID: 30761640
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SUSTAINED VIROLOGIC RESPONSE RATE IN CHRONIC HEPATITIS C PATIENTS THROUGH DIRECT-ACTING ANTIVIRALS THERAPY.
    Torres AD; Sparvoli JMH; Sparvoli AC; Gonçalves CV
    Arq Gastroenterol; 2019; 56(4):394-398. PubMed ID: 31800735
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of a Hepatitis C Patient Management Program at a University Specialty Pharmacy.
    Zaepfel M; Cristofaro L; Trawinski A; McCarthy K; Rightmier E; Khadem T
    Ann Pharmacother; 2017 Apr; 51(4):307-314. PubMed ID: 28228059
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HCV core antigen as an alternative to HCV RNA testing in the era of direct-acting antivirals: retrospective screening and diagnostic cohort studies.
    van Tilborg M; Al Marzooqi SH; Wong WWL; Maan R; Vermehren J; Maasoumy B; Mazzulli T; Bolotin S; Garber G; Guerra F; Flud CR; Kowgier M; Janssen HL; de Knegt RJ; Pawlotsky JM; Cloherty GA; Duarte-Rojo A; Sarrazin C; Wedemeyer H; Feld JJ
    Lancet Gastroenterol Hepatol; 2018 Dec; 3(12):856-864. PubMed ID: 30274834
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Measuring Adherence to Hepatitis C Direct-Acting Antiviral Medications: Using the VAS in an HCV Treatment Clinic.
    Burton MJ; Voluse AC; Patel AB; Konkle-Parker D
    South Med J; 2018 Jan; 111(1):45-50. PubMed ID: 29298369
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The combination of pill count and self-reported adherence is a strong predictor of first-line ART failure for adults in South Africa.
    Wu P; Johnson BA; Nachega JB; Wu B; Ordonez CE; Hare AQ; Kearns R; Murphy R; Sunpath H; Marconi VC
    Curr HIV Res; 2014; 12(5):366-75. PubMed ID: 25426940
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of pill burden on adherence to hepatitis C medication.
    An J; Lee JS; Sharpsten L; Wilson AK; Cao F; Tran JN
    Curr Med Res Opin; 2019 Nov; 35(11):1937-1944. PubMed ID: 31298592
    [No Abstract]   [Full Text] [Related]  

  • 10. [Self-reported experience in patients treated with Hepatitis C direct acting antivirals].
    Cañamares Orbis I; Saez de la Fuente J; Izquierdo García E; Esteban Alba C; Such Díaz A; Escobar Rodríguez I
    Farm Hosp; 2016 Nov; 40(n06):569-578. PubMed ID: 27894229
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hepatitis C virus direct-acting antiviral nonadherence: Relationship to sustained virologic response and identification of at-risk patients.
    Slevin AR; Hart MJ; Van Horn C; Rahman S; Samji NS; Szabo A; Rein L; Werner S; Saeian K
    J Am Pharm Assoc (2003); 2019; 59(1):51-56. PubMed ID: 30545782
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of six methods to estimate adherence in an ART-naïve cohort in a resource-poor setting: which best predicts virological and resistance outcomes?
    Orrell C; Cohen K; Leisegang R; Bangsberg DR; Wood R; Maartens G
    AIDS Res Ther; 2017 Apr; 14(1):20. PubMed ID: 28376815
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pre- Versus Posttransplant Treatment of Hepatitis C Virus With Direct-Acting Antivirals in Liver Transplant Recipients: More Issues to be Solved.
    Abdelqader A; Kabacam G; Woreta TA; Hamilton JP; Luu H; Al Khalloufi K; Saberi B; Philosophe B; Cameron AM; Gurakar A
    Exp Clin Transplant; 2017 Feb; 15(Suppl 1):1-5. PubMed ID: 28260422
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Significance of day-1 viral response of hepatitis C virus in patients with chronic hepatitis C receiving direct-acting antiviral therapy.
    Toyoda H; Kumada T; Tada T; Yama T; Mizuno K
    J Gastroenterol Hepatol; 2018 Jun; 33(6):1264-1270. PubMed ID: 29164675
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Direct-acting antivirals in hepatitis C virus (HCV)-infected and HCV/HIV-coinfected patients: real-life safety and efficacy.
    Milazzo L; Lai A; Calvi E; Ronzi P; Micheli V; Binda F; Ridolfo AL; Gervasoni C; Galli M; Antinori S; Sollima S
    HIV Med; 2017 Apr; 18(4):284-291. PubMed ID: 27477612
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of partial reimbursement on hepatitis B antiviral utilization and adherence.
    Qiu Q; Duan XW; Li Y; Yang LK; Chen Y; Li H; Duan ZP; Wang L
    World J Gastroenterol; 2015 Aug; 21(32):9588-97. PubMed ID: 26327766
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Outcomes of treatment with direct-acting antivirals for infection with hepatitis C virus genotypes 1-4 in an ambulatory care setting.
    Bach TA; Zaiken K
    Am J Health Syst Pharm; 2017 Mar; 74(5 Supplement 1):S1-S9. PubMed ID: 28213381
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recurrent hepatitis C treatment with direct acting antivirals - a real life study at a Brazilian liver transplant center.
    Zanaga LP; Santos AG; Ataíde EC; Boin IFSF; Stucchi RSB
    Braz J Med Biol Res; 2019; 52(8):e8519. PubMed ID: 31389490
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunosuppressive and antiviral treatment of hepatitis C virus-associated glomerular disease: A long-term follow-up.
    Fabrizi F; Aghemo A; Lampertico P; Fraquelli M; Cresseri D; Moroni G; Passerini P; Donato FM; Messa P
    Int J Artif Organs; 2018 Jun; 41(6):306-318. PubMed ID: 29595085
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Validation of patient reports, automated pharmacy records, and pill counts with electronic monitoring of adherence to antihypertensive therapy.
    Choo PW; Rand CS; Inui TS; Lee ML; Cain E; Cordeiro-Breault M; Canning C; Platt R
    Med Care; 1999 Sep; 37(9):846-57. PubMed ID: 10493464
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.